The Gucci Clock

ISSUE 09 · MAY 26, 2026 · COTY $2.03

On December 22, 2025, the Monday before Christmas, Coty Inc. announced that Sue Nabi — the CEO who had spent four years rebuilding the company's prestige fragrance business into what she called a "scenting powerhouse" — was gone. No transition plan. No successor named. Just a press release, a $1.74 million severance check, and the appointment of Markus Strobel, a 33-year Procter & Gamble veteran, as interim CEO and executive chairman, effective January 1.

Six weeks later, on February 5, 2026, Strobel sat on his first earnings call and delivered the kind of quarter that makes securities lawyers reach for their filing templates. Consumer Beauty operating income had plummeted over 70% year-over-year. Prestige operating income was down 18%. Organic revenue fell 9%. And then the real bomb: Coty withdrew its full-year fiscal 2026 EBITDA and free cash flow guidance entirely. The company that had been guiding to $1 billion in adjusted EBITDA just three months earlier was now telling investors it could not predict its own profitability.

The stock dropped 22% in two days.

Since then, Coty has announced a strategic review of its entire Consumer Beauty division — the $1.2 billion mass-market segment that includes CoverGirl, Rimmel, Sally Hansen, and Max Factor — and a securities class action lawsuit has been filed alleging the company concealed deteriorating business trends throughout 2025. The 52-week high was $5.34. The stock sits at $2.03. And the Gucci fragrance license, which generates an estimated $550 million in annual revenue, expires in 2028.

That is a lot of bad news. But it is not the whole story.

In June 2025, Coty touched $5.34 — a 52-week high driven by the perceived success of Nabi's turnaround strategy. The prestige fragrance portfolio (Hugo Boss, Burberry, Marc Jacobs, Chloe) had grown at a 10% CAGR from FY2021 to FY2025, with individual brands posting gains of 30% to 140% over that period. Hugo Boss fragrances had become a global top-five prestige scent. The Wella divestiture was complete, bringing in $750 million in cash. Leverage was coming down. The stock was a restructuring success story.

Then three things happened in rapid succession.

The CEO exit. Sue Nabi's departure on December 22, 2025, shattered the narrative. Nabi had been the architect of Coty's prestige pivot — the strategy that took a company known for CoverGirl and turned it into a serious fragrance house. Her exit, with no successor named and no operational explanation, signaled to the market that something was wrong behind the scenes. The stock dropped from $4.20 to $3.80 on the news.

The earnings catastrophe. On February 5, 2026, the Q2 FY2026 report revealed the scale of the deterioration. Revenue of $1.68 billion missed the bar. Adjusted operating income fell 18% to $274 million. Consumer Beauty's operating income collapsed by more than 70%. Most critically, the company withdrew its full-year guidance — the single strongest signal a management team can send that it has lost visibility into its own business. The stock fell from $3.43 to $2.66 in two sessions.

The Gucci clock. In the weeks that followed, the market absorbed a fact that had been public but under-appreciated: Coty's license to produce and distribute Gucci fragrances expires in 2028, after which L'Oréal takes over under a 50-year exclusive deal. Gucci is Coty's third-largest fragrance brand, generating an estimated $500–$600 million in annual revenue and roughly 12.5% of total company EBITDA. The expiration is not a risk. It is a certainty. And the replacement revenue does not yet exist.

The combination — CEO departure, earnings collapse, guidance withdrawal, securities lawsuit, and a ticking clock on a half-billion-dollar revenue stream — took Coty from $5.34 to $1.95 (the 52-week low, hit on April 2, 2026). The stock bounced slightly on the Q3 FY2026 earnings beat in May, which cleared a dramatically reduced bar. It trades today at $2.03.

That is how Coty got here.

The story this table tells is more nuanced than the stock price suggests. Revenue is falling, but adjusted EBITDA of $838–848 million means Coty is still generating roughly $840 million in operating profit on a $5.7 billion revenue base — a 14.7% margin. Free cash flow of $276 million in nine months covers debt service. The Wella sale brought leverage down to 2.7x at Q2 before seasonal working capital pushed it to 3.4x at Q3. The company is not in distress. It is in transition.

What the table does NOT tell you is whether the transition will succeed before the Gucci clock runs out. That is worth approximately $550 million in annual revenue and the difference between a $2 stock and a $5 stock.

Coty is a wholesale beauty conglomerate, not a DTC brand. The corporate entity "Coty Inc." has minimal consumer-facing presence. The consumer voice data in this report comes from Coty's individual brands — the entities that actual customers interact with.

Important caveat on consumer data. Coty's business model is B2B — it sells through Ulta, Sephora, Walmart, and department stores, not primarily through its own e-commerce. As a result, consumer-review platforms capture only a fraction of the customer base, and that fraction is skewed toward complaint-motivated reviewers. The Kylie Cosmetics Trustpilot sample (4,831 reviews) is the most robust data source available. CoverGirl's PissedConsumer sample (571) is directionally useful but not representative. We are transparent about these limitations.

The central question for Coty investors is not whether the company is declining — it is — but whether the decline is uniform or concentrated. If both segments are falling at the same rate, the entire company is in trouble. If Consumer Beauty is falling faster, the strategic review (and potential divestiture) becomes a catalyst.

We ran a paired t-test on seven quarters of like-for-like sales growth (Q1 FY2025 through Q3 FY2026) for both segments.

Consumer Beauty LFL: +1%, -3%, -6%, -12%, -5%, -6%, -9%

Prestige LFL: +4%, 0%, -1%, -7%, -1%, -1%, -5%

Gap (CB minus Prestige): -3, -3, -5, -5, -4, -5, -4

Mean gap: -4.14 percentage points per quarter (95% CI: -4.81 to -3.48). Paired t = -12.18, p < 0.00002.

Consumer Beauty is declining at a rate that is statistically and economically significantly faster than Prestige — by an average of 4.1 percentage points per quarter, every quarter, for nearly two years. The gap is remarkably stable: it never drops below 3 points or exceeds 5. This is not random noise. This is a structural divergence.

The implication is direct: if Coty can successfully divest or restructure Consumer Beauty (the strategic review's stated aim), the remaining Prestige business — while still declining — is declining at roughly half the rate. And Prestige carries a 22% operating margin versus Consumer Beauty's 8%. The math favors the surgery.

We ran a Mann-Kendall trend test on the seven quarters of consolidated LFL sales growth.

Kendall tau = -0.571, Z = -1.65, p = 0.099. The test does not reach statistical significance at the 5% level, though it approaches it. The reason: the Q1 FY2026 data point (-2%) represents an improvement over Q4 FY2025 (-9%), breaking the monotonic pattern. A linear regression yields a slope of -1.18 percentage points per quarter (95% CI: -2.40 to +0.04, R² = 0.42).

In plain language: there is a downward trend, but the quarterly data is noisy enough — and the sample small enough at seven quarters — that we cannot confidently reject the null hypothesis of no trend at p < 0.05. The improvement from Q4 FY2025 to Q1 FY2026 may be genuine (easier comps, Strobel's cost cuts taking hold) or it may be seasonal. The Q4 FY2026 result will clarify this.

This matters for the trade. If you believe the Q1 improvement is the beginning of a bottoming process, the stock at $2.03 is mispriced. If you believe it is noise in a continuing decline, $2.03 has further to fall. The data does not yet resolve this ambiguity — which is exactly why the stock is trading where it is.

The financials show a company in decline. What they do not show is the strategic optionality that the new CEO is building — or the ticking time bomb that makes that optionality urgent.

The Gucci clock. Coty's license to produce Gucci fragrances expires in 2028. L'Oréal has already signed a 50-year exclusive deal for the post-Coty era. Gucci generates roughly $550 million in annual revenue for Coty and an estimated 12.5% of total EBITDA. When that license expires, Coty loses nearly $100 million in annual EBITDA overnight. That is not a risk to be managed — it is a scheduled amputation.

Strobel's response is the "Coty.Curated" strategy: double down on the remaining prestige fragrance brands (Hugo Boss, Burberry, Marc Jacobs, Chloe, Kylie), integrate prestige and mass fragrances under one division, and use the proceeds from a Consumer Beauty divestiture to de-lever the balance sheet before the Gucci revenue disappears. The logic is sound. The timeline is brutal.

The employee picture. Glassdoor paints a company under stress. Of 1,867 reviews, the overall rating is 3.5/5 — respectable on the surface. But recent reviews from the transformation period tell a different story. Employees describe multiple rounds of layoffs (400+ positions cut), understaffed teams, and what one R&D scientist called a very toxic workplace. The CEO approval percentage and the "recommend to a friend" metric (64%) are both lower than industry peers like L'Oréal and Estée Lauder. The transformation savings are real — $200 million in cumulative fiscal 2026 cost cuts — but they come at a morale cost that the financials cannot measure.

The brand divergence. Kylie Cosmetics, the prestige brand Coty is keeping, has 4,831 Trustpilot reviews at 3.2 stars with a bimodality coefficient of 0.83 — meaning customers either love it or hate it. CoverGirl, the mass brand under strategic review, has 571 PissedConsumer reviews at 2.8 stars with recurring complaints about product reformulation, shrinkflation, and discontinued favorites. Sally Hansen, also under review, is the exception — its Miracle Gel line won beauty awards in 2025 and consumers consistently praise the value. If Coty sells Consumer Beauty, Sally Hansen may be the asset that fetches the premium.

Recovering:

The prestige fragrance core. Hugo Boss, Burberry, Marc Jacobs, and Chloe each grew 30%–140% from FY2019 to FY2025. Even in FY2026's difficult environment, Prestige is declining at half the rate of Consumer Beauty. The balance sheet improved with the Wella divestiture bringing in $750M and leverage dropping from 3.7x to 2.7x at Q2. Free cash flow of $276M in 9 months covers debt service. Management credibility is being rebuilt — Strobel's "Coty.Curated" strategy is clearly articulated, the strategic review has a timeline, and five new independent directors have been appointed.

NOT recovering (yet):

Consumer Beauty. Operating income down 70%+ in Q2, LFL sales down 9% for the segment, and the strategic review has not yet produced a buyer or a deal. The Gucci replacement — no new license has been announced to replace the ~$550M in revenue that expires in 2028. The clock is ticking and the cupboard, so far, is bare. Investor trust remains damaged — the securities class action (Hagens Berman, class period May 2025–Feb 2026) alleges concealed deteriorating trends, and institutional capital will remain cautious until resolved.

Unknown:

Whether the Consumer Beauty strategic review will produce a sale, a spin-off, or a restructuring — and at what valuation. Whether Strobel will be named permanent CEO or whether a new external search is underway. Whether the Gucci license loss is already priced in at $2.03, or whether the market has further to discount.

1. Consumer-review data for Coty is structurally thin. Coty is a wholesale conglomerate. Its brands sell through third-party retailers. The consumer-facing review platforms capture a tiny, complaint-skewed slice of actual customer experience. The Kylie Cosmetics Trustpilot data (4,831 reviews) is the richest source, but it is not representative of the full Coty customer base.

2. The segment LFL data uses Turnaround Radar estimates for quarters where Coty did not disclose individual segment quarterly growth. Our estimates are calibrated to match reported annual and half-year segment figures and are robust to reasonable variation.

3. The Gucci revenue estimate ($550M) is a consensus analyst figure, not a Coty disclosure. Coty does not break out individual brand revenue. The range across analyst reports is $500–$600M. We use the midpoint.

4. The securities lawsuit is an allegation, not a finding. The class action has been filed but not adjudicated. The outcome is uncertain and the settlement range is wide.

The trade turns on whether Coty can execute two transitions simultaneously: divest Consumer Beauty at a reasonable valuation, and replace Gucci's revenue before the 2028 license expiration.

Bear case (30% probability): The Consumer Beauty strategic review fails to find a buyer at an acceptable price. The Gucci replacement revenue never materializes. LFL sales continue to decline through FY2027. The securities lawsuit results in a material settlement. Leverage creeps back above 4x. The stock reprices to $0.80–$1.20 — effectively a distressed-debt scenario where the equity is subordinate to $3.2B in debt.

Base case (45% probability): The Consumer Beauty divestiture closes in H1 FY2027 at 5–7x EBITDA ($400–$560M), with proceeds used to de-lever. Strobel is named permanent CEO. Prestige LFL stabilizes at flat-to-slightly-positive. The Gucci loss is partially offset by new license wins. Price target: $3.00–$4.00 within 12 months.

Bull case (25% probability): Everything in the base case, plus: Coty announces a replacement fragrance license of comparable scale. Consumer Beauty sale fetches a premium (8x+ EBITDA) due to Sally Hansen's brand strength. The securities lawsuit settles for a manageable amount. The stock re-rates as a pure-play prestige fragrance company. Price target: $5.50–$7.00 within 12 months.

Expected value: ~$3.44, roughly 69% above current. The risk/reward is favorable but the variance is extreme. This is a restructuring bet with a hard catalyst calendar, not a quality compounder.

Now ($2.03): The stock is pricing in a high probability of the bear case — the market essentially values Coty's equity as if the Gucci loss, the Consumer Beauty drag, and the securities lawsuit will all resolve unfavorably. If you believe even one of those three will break better than feared, the stock is mispriced.

Next catalyst: Consumer Beauty strategic review conclusion (by end of FY2026, June 2026). Strobel committed to completing the review by fiscal year-end. An announcement of a sale, spin-off, or restructuring plan would remove the largest source of uncertainty and give the market a standalone Prestige valuation to anchor on. This is the near-term catalyst that matters most.

Decider date: Q4 FY2026 earnings (August 2026). This report will contain the full-year FY2026 results, the first FY2027 guidance under Strobel, and likely the strategic review outcome. If FY2027 guidance shows Prestige LFL stabilizing at flat-to-positive and a credible Consumer Beauty exit, the re-rating begins. If FY2027 guidance shows continued broad-based decline and no CB resolution, the bear case gains weight.

The ladder:

$1.50–1.80: Add aggressively if the stock retests the 52-week low on no new negative news. At that level, you are paying roughly 3x EV/EBITDA for a company with $840M in adjusted EBITDA and $276M in 9-month FCF.

$2.03 (current): Small position if you believe the strategic review will produce a credible outcome by June. The risk/reward at 3.5x EV/EBITDA is attractive, but the Gucci overhang and lawsuit risk merit sizing conservatively.

$3.50–4.00: Take partial profits on the first re-rating move. The easy money is the gap between distressed pricing and restructuring pricing.

When Coty reports Q4 FY2026 earnings in August, subscribers will get:

Consumer Beauty strategic review outcome. If a divestiture or spin-off has been announced, we will value the transaction and assess its impact on Coty's go-forward leverage and earnings profile. If the review concludes without a sale, we will assess the restructuring alternative and its implications for the equity.

FY2027 guidance and Gucci replacement update. The first forward guidance under Strobel as a pure going-concern. We will compare the FY2027 EBITDA guide to the post-Gucci run-rate and assess whether the gap is closing.

Securities lawsuit update. By August, the lead plaintiff will have been appointed and early settlement discussions may be underway. We will assess the likely range and its materiality to the equity.

That is the next dated read. It lands in August. Mark it: calendar.turnaroundradar.com.

Turnaround Radar is a research newsletter. Nothing here is investment advice. We have no position in COTY and no relationship with the company. All data sourced from public filings, Trustpilot, PissedConsumer, Glassdoor, and the platforms cited above.